Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00238316 · ClinicalTrials.gov registry record · Phase 2

Letrozole in Preventing Breast Cancer in Postmenopausal Women Who Are at Increased Risk for Breast Cancer Due to High Breast Density

A Phase 2 study of Breast Cancer, sponsored by NCIC Clinical Trials Group.

Completed
Registry status
Phase 2
Development phase
68
Enrollment target
10
Study locations

NCT00238316 is a Phase 2 study of Breast Cancer that has completed, run by NCIC Clinical Trials Group. The registered enrollment target is 68 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 10 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00238316, a Phase 2 study of Breast Cancer, has completed, sponsored by NCIC Clinical Trials Group.

COMPLETED
Registry status
Phase 2
Development phase
68 participants
Enrollment target
10
Study locations

Study Summary

RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of letrozole may stop cancer from forming or coming back in postmenopausal women who are at increased risk for breast cancer due to high breast density. PURPOSE: This randomized phase II trial is studying how well letrozole works in preventing breast cancer in postmenopausal women who are at increased risk for breast cancer due to high breast density.

Conditions Studied

Breast Cancer

Interventions

  • OTHER Placebo
  • DRUG letrozole

Study Locations (10)

Ontario

  • Hamilton Osteoporosis Diagnostic Services - Hamilton
  • Ottawa Hospital Regional Cancer Centre - General Campus - Ottawa
  • St. Catharines General Hospital at Niagara Health System - St. Catharines
  • Toronto Sunnybrook Regional Cancer Centre at Sunnybrook Health Sciences Centre - Toronto
  • Princess Margaret Hospital - Toronto

Massachusetts

  • Massachusetts General Hospital Cancer Center - Boston
  • Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute - Boston

Alberta

  • Tom Baker Cancer Centre - Calgary - Calgary

Nova Scotia

  • Nova Scotia Cancer Centre - Halifax

Quebec

  • Hotel Dieu de Montreal - Montreal

Trial Details

FieldValue
Enrollment Target 68 participants
Start Date 2000-12-05
Est. Completion 2009-02-10
Phase Phase 2

Sponsor

NCIC Clinical Trials Group

21 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00238316

The ClinicalTrials.gov registry entry for NCT00238316 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The listed sponsor is NCIC Clinical Trials Group, which has 21 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00238316 reports 10 study locations spanning 5 distinct geographic areas - top geographies include Ontario, Massachusetts, Alberta.

Frequently Asked Questions

What is clinical trial NCT00238316 about?

NCT00238316 is a clinical study titled "Letrozole in Preventing Breast Cancer in Postmenopausal Women Who Are at Increased Risk for Breast Cancer Due to High Breast Density". RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of letrozole may stop cancer from forming or coming back in postmenopausal women who are at increased risk for breast cancer due to high breast density. PURPOSE: This randomized phas...

What is the current status of trial NCT00238316?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2000-12-05. Estimated completion is 2009-02-10.

What conditions does trial NCT00238316 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT00238316?

The interventions under investigation include: Placebo (OTHER), letrozole (DRUG).

Who is sponsoring clinical trial NCT00238316?

This trial is sponsored by NCIC Clinical Trials Group, which has 21 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00238316 being conducted?

This trial has 10 study locations across Massachusetts, Alberta, Nova Scotia, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.